Results of a retrospective study of the clinical efficacy and safety of insulin RinFast® in children with type 1 diabetes mellitus

BACKGROUND: The relevance of the study is justified by the fact that in recent years, the original insulin preparations have been replaced with biosimilars in the regions of the Russian Federation, but there are currently few studies describing the use of insulin biosimilars in children with type 1 diabetes mellitus (DM1), both in domestic and foreign sources.

AIM: To evaluate the efficacy and safety insulin therapy with RinFast® (GEROPHARM LLC, Russia) as bolus therapy in combination with long-acting insulin and as monotherapy in an insulin pump in children with DM1 in real clinical practice.

MATERIALS AND METHODS: The dynamics of HbA^1c after 3 and 6 months, the change in daily insulin requirements, the fre quency of episodes of postprandial hyper- and hypoglycemia, adverse reactions at injection sites, the number of patients who reached the target values of HbA^1c in children with DM1 who received RinFast® at least 6 months after the original analogue of insulin aspart were evaluated.

RESULTS: The study was conducted in 50 children with DM1 from 1 to 18 years old (average age 9.8±4.6 years), with a duration of DM1 of more than 1 year (average duration 3.5±2.1 years), who had glycated hemoglobin (HbA^1c) at the beginning of follow-up of no more than 9.5% and received biosimilar RinFast® for at least 6 months after the transfer from the original analogue of insulin aspart. Basic bolus insulin therapy in 36 children was carried out using multiple injections of insulin (MII), in 14 — continuous supply of insulin (NPI) using an insulin pump. The study resulted in HbA1c levels comparable to the baseline 3 and 6 months after the start of therapy with the RinFast® biosimilar (p=0.05), no changes in the daily ­insulin ­requirement (p=0.05) and no increase in the frequency of episodes of postprandial hyper- (p=0.05) and hypoglycemia (p=0.05) and adverse events (p=0.05). High adherence to treatment with the RinFast® biosimilar was noted.

CONCLUSION: The results obtained indicate the absence of a clinically significant deterioration in glycemic control indicators after the transfer of children with DM1 to therapy with the RinFast® biosimilar, which makes it possible to use it safely and effectively in this category of patients.

1. Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV, Isakov MА. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Diabetes mellitus. 2021;24(3):204-221. (In Russ.) https://doi.org/10.14341/DM12759

2. International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium: International Diabetes Federation, 2021

3. Dedov II, Shestakova M V., Mayorov AY, et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 11th edition. Diabetes mellitus.. 2023;26(2S):1-157. (In Russ.) https://doi.org/10.14341/DM13042

4. Jovanovic L, Giammattei J, Acquistapace M, Bornstein K, Sommermann E, Pettitt DJ. Efficacy Comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size. Clin Ther. 2004;26(9):1492-1497. https://doi.org/10.1016/j.clinthera.2004.09.001

5. Natsional'nye rekomendatsii Rossiiskogo nauchnogo meditsinskogo obshchestva terapevtov po kolichestvennoi otsenke priverzhennosti k lecheniyu. — M., 2017. — 24 p. (In Russ.)

6. Heinemann L. Biosimilar Insulin and Costs. J Diabetes Sci Technol. 2016;10(2):457-462. https://doi.org/10.1177/1932296815605337

7. Karonova Т.L., Mayorov A.Y. Study of equivalence and comparable immunogenicity of biosimilar insulin aspart in comparison with the registered analogue. Medical Council. 2022;(10):75-82. (In Russ.). https://doi.org/10.21518/2079-701X-2022-16-10-75-82 https://doi.org/10.21518/2079-701Х-2022-16-10-75-82